Table 1 Clinical features and EYA2 protein expression in patients with HCC (n = 94)
Clinicopathological | EYA2 protein expression | P value | |
|---|---|---|---|
variables | High (n = 44, 46.81%) | Low (n = 50, 53.19%) | |
Age (years) | |||
  ≥ 50 | 31 (32.98%) | 27 (28.72%) | 0.102 |
  < 50 | 13 (13.83%) | 23 (24.47%) |  |
Gender | |||
 Male | 39 (41.49%) | 43 (45.74%) | 0.702 |
 Female | 5 (5.32%) | 7 (7.45%) |  |
Tumor number | |||
 single | 32 (34.04%) | 37 (39.36%) | 0.889 |
 multiple | 12 (12.77%) | 13 (13.83%) |  |
Tumor size (cm) | |||
  < 5 | 24 (25.53%) | 11 (11.70%) | 0.001 |
  ≥ 5 | 20 (21.28%) | 39 (41.49%) |  |
Liver cirrhosis | |||
 Yes | 31 (32.98%) | 30 (31.91%) | 0.289 |
 No | 13 (13.83%) | 20 (21.28%) |  |
Serum AFP (ng/ml) | |||
  ≤ 20 | 19 (20.21%) | 14 (14.89%) | 0.124 |
  > 20 | 25 (26.60%) | 36 (38.30%) |  |
HBsAg | |||
 Positive | 41 (43.62%) | 43 (45.74%) | 0.429 |
 Negative | 3 (3.19%) | 7 (7.45%) |  |
BCLC stage | |||
 0–A | 23 (24.47%) | 14 (14.89%) | 0.016 |
 B–C | 21 (22.34%) | 36 (38.30%) |  |
TNM stage | |||
 I | 30 (31.91%) | 28 (29.79%) | 0.225 |
 II–IV | 14 (14.89%) | 22 (23.40%) |  |
Tumor differentiation | |||
 I–II | 21 (22.34%) | 14 (14.89%) | 0.048 |
 III–IV | 23 (24.47%) | 36 (38.30%) |  |